Brief: Lipidor: Positive Topline Results Of AKP01 Phase III Clinical Study

Lipidor AB

24/01/2020 14:24

Jan 24 (Reuters) - Lipidor AB  LIPI.ST :
    * LIPIDOR ANNOUNCES POSITIVE TOPLINE RESULTS OF AKP01 PHASE
III
CLINICAL STUDY USING CALCIPOTRIOL SPRAY AGAINST PSORIASIS
    * RANDOMISED 277-PATIENT STUDY ACHIEVED ITS PRIMARY ENDPOINT
DEMONSTRATING THERAPEUTIC EQUIVALENCE TO COMPARATOR MEASURED AS
REDUCTION OF PASI SCORE
    * BOTH LIPIDOR'S AKP01 AND COMPARATOR HAD A STATISTICALLY
SIGNIFICANTLY BETTER EFFICACY COMPARED TO PLACEBO
    * AKP01 WAS WELL TOLERATED THROUGH 8 WEEKS OF STUDY DRUG
ADMINISTRATION
    * INCIDENCE OF ADVERSE EVENTS WAS LOW IN ALL TREATMENT
GROUPS
    * ALL ADVERSE EVENTS WERE MILD OR MODERATE, WITH NO SERIOUS
ADVERSE EVENTS REPORTED
    * TOPLINE RESULTS OF ANALYSIS OF STUDY DEMONSTRATED
THERAPEUTIC
EQUIVALENCE TO COMPARATOR IN REDUCING PSORIASIS SYMPTOMS
ACCORDING TO PASI SCALE

Source text for Eikon:  ID:nWkr8xndvF 
Further company coverage:  LIPI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))